Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Chief Medical Officer | May 01, 2023 | May 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date May 01, 2023 · Filed May 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,000 |
Reported balance
After 2023-05-01 transaction · row 1
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 35,000 · Balance 35,000 F1: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2033-05-01 | Direct | 80,000 |
Reported balance
After 2023-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-01 · Grant · Acquired 80,000 · Balance 80,000 F2: The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.
F2: The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2023 Filed May 1, 2023 20:24 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001104659-23-054393 · tm2313994-2_4seq1.xml · derivative · entry 2 Taylor Kirk · CIK 0001975703 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-05-01 F2 · derivative.exercise_date: The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. Read SEC document |
| May 01, 2023 Filed May 1, 2023 20:24 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-054393 · tm2313994-2_4seq1.xml · nonDerivative · entry 1 Taylor Kirk · CIK 0001975703 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.